The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells
Open Access
- 1 February 2017
- journal article
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 36, 120-124
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Differential Expression of 2′,3′-Cyclic-Nucleotide 3′-Phosphodiesterase and Neural Lineage Markers Correlate with Glioblastoma Xenograft Infiltration and Patient SurvivalClinical Cancer Research, 2012
- Tumor treating fields: concept, evidence and futureExpert Opinion on Investigational Drugs, 2011
- Guidelines for accurate EC50/IC50 estimationPharmaceutical Statistics, 2011
- TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transportersBMC Cancer, 2010
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields)BMC Medical Physics, 2009
- Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumorsProceedings of the National Academy of Sciences, 2007
- Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell linesCancer Cell, 2006
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005